Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Solid Cancers
Interventions: carboplatin, docetaxel, trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 16 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more

Conditions: Cancer
Interventions: palivizumab, ribavirin; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Squamous Non-small Cell Lung Cancer
Interventions: Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 8 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more

Conditions: Acute Stroke
Interventions: SA controller, TA controller, SA controller early testing; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cardiac Arrest (CA)
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 37 Weeks to 18 Years
Enrollment: 1,620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 22
States / cities: Orange, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Graft-versus-Host Disease
Interventions: Methoxsalen, Extracorporeal Photopheresis; Drug · Procedure
Lead sponsor: Mallinckrodt; Industry
Eligibility: Not listed
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 11
States / cities: Little Rock, Arkansas • Gainesville, Florida • Chicago, Illinois + 6 more

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse, Other B Cell Lymphoma in Relapse, Plasma Cell Leukemia
Interventions: SNS01-T; Biological
Lead sponsor: Senesco Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Little Rock, Arkansas • Rochester, Minnesota • Hackensack, New Jersey + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: minocycline; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 30
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 25 more

Conditions: Myelofibrosis
Interventions: KRT-232, Ruxolitinib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more

Conditions: Acute Lymphoblastic Leukemia/Lymphoma, Myelodysplasia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Up to 22 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 32
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Catheter-Related Infections
Interventions: Mino-Lok Therapy (MLT); Drug
Lead sponsor: Leonard-Meron Biosciences, Inc.; Industry
Eligibility: 12 Years and older
U.S. locations: 27
States / cities: Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more

Conditions: Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: zoledronic acid, quality-of-life assessment; Drug · Procedure
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 55
States / cities: Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more

Conditions: Unruptured Wide-neck Aneurysms
Interventions: Citadel Embolization Device; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Walnut Creek, California + 18 more

Conditions: Breast Cancer
Interventions: HCQ, Avelumab, Palbociclib; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions: SAR443579; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: busulfan, melphalan, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Contraceptive Usage
Interventions: Norethindrone Acetate; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,659 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 50 more

Conditions: Acute Otitis Media
Interventions: Hyland's earache drops; Drug
Lead sponsor: University of Washington; Other
Eligibility: 6 Months to 11 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Previously Treated PH + CML
Interventions: Bosutinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Deerfield Beach, Florida • Miami, Florida + 6 more

Conditions: Coronary Artery Disease
Interventions: Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG); Device · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 23 more

Conditions: Leiomyoma
Interventions: BAY1002670, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more

Search by objective public record fields.

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

An Upper Extremity Exoskeleton to Target Unwanted Joint Synergies During Repetitive Training in Stroke Survivors

Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Minocycline to Treat Amyotrophic Lateral Sclerosis

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Citadel Embolization Device Study

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

Ear Drops for Children With Otitis Media

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Coronary Artery Revascularization in Diabetes

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap